Company Overview of ALS Therapy Development Institute
215 1st Street
Cambridge, MA 02142-1236
Key Executives for ALS Therapy Development Institute
Chief Executive Officer and Chief Scientific Officer
Director of Communications & Public Affairs
Compensation as of Fiscal Year 2013.
ALS Therapy Development Institute Key Developments
ALS Therapy Development Institute and Neurimmune Partner to Advance Treatments for ALS
Dec 6 13
ALS Therapy Development Institute together with its wholly-owned subsidiary, Anelixis Therapeutics, announced that it has formed a research partnership with Neurimmune to advance potential treatments for ALS, also known as Lou Gehrig's disease. The research partnership will explore a human monoclonal antibody that targets misfolded superoxide dismutase 1 (SOD1). Misfolded SOD1 accumulates in familial and sporadic ALS, suggesting a generalized role as a drug target for ALS treatments. The collaboration will explore the high-affinity human antibodies developed by Neurimmune that selectively target misfolded SOD1. In preclinical studies with transgenic mice, chronic antibody treatment significantly reduced SOD1 pathology and rescued spinal cord motor neurons, resulting in significantly reduced muscle atrophy, better motor functions and increased survival.
The ALS Therapy Development Institute Appoints Jennifer 'Jenny' Gore Dwyer of Kenmore to its Board of Directors
Oct 1 13
The ALS Therapy Development Institute (ALS TDI) announced that it has elected Jennifer 'Jenny' Gore Dwyer of Kenmore, WA, to its Board of Directors. Dwyer is part of a wave of additions to the board this year, as ALS TDI looks to grow and accelerate its drug development and venture philanthropy programs designed to end ALS. The Institute's board has grown to include 15 members with deep ties to the ALS community and vast experience in leadership positions across multiple industries.
ALS Therapy Development Institute Adds Two Board Members
May 2 13
The ALS Therapy Development Institute announced that it has added two members to its board of directors: Robert Sepucha Jr. and Michael M. Smith. The Institute's board grows to include 14 members with deep ties to the ALS community, academic research, philanthropy and pharmaceutical development. Robert Sepucha Jr. is senior vice president, policy and business development for Fresenius Medical Care North America. Prior to joining Fresenius, Sepucha served as general counsel for the Massachusetts Life Science Center, as well as chief of staff and senior policy advisor to Congressman Harold Ford Jr. (D-TN), where he was the Congressman's primary advisor on legislative strategy, political activities, media strategy and legal issues. Michael M. Smith is president of B.T. Loftus Ranches Inc. He is also founder, director and former president of Yakima Chief Inc., an international hops sales organization.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries